
## Videoconference


2021 Half-Year financial results

April-September, 2021



<b>mdc-GRT</b> Tacrolimus Transplantation	<b>mdc-ANG</b> Confidential Antipsychotic					
<b>mdc-STM</b> Ivermectin Malaria	<b>mdc-WWM</b> Progestatif (non-MPA) Contraception	<b>mdc-TJK</b> Confidential Antipsychotic				
mdc-KPT Confidential Pain	<b>mdc-TTG</b> Ivermectine Covid-19	<b>mdc-CWM</b> Celecoxib Pain & inflammation		<b>mdc-IRM</b> Risperidone Schizophrenia		
Preclinical		Phase 1/2	Phase 3	NDA <sup>*</sup> / Market		
				*New Drug Application		
In partnership with Teva Pharmaceuticals In partnership with AIC			Supported by the Bill & Melinda Gates Foundation   Supported by Unitaid			
Internal programs		Animal Health product (different clinical develop	Animal Health product (different clinical development process)			

<b>mdc-GRT</b> Tacrolimus Transplantation	<b>mdc-ANG</b> Confidential Antipsychotic			
<b>mdc-STM</b> Ivermectin Malaria	<b>mdc-WWM</b> Progestatif (non-MPA) Contraception	<b>mdc-TJK</b> Confidential Antipsychotic		
mdc-KPT Confidential Pain	<b>mdc-TTG</b> Ivermectine Covid-19	<b>mdc-CWM</b> Celecoxib Pain & inflammation		<b>mdc-IRM</b> Risperidone Schizophrenia
Preclinical		Phase 1 / 2	Phase 3	NDA <sup>*</sup> / Market
				*New Drug Application
In partnership w	vith Teva Pharmaceuticals	Supported by the Bill & Melinda Gates Foundation		
In partnership with AIC		Supported by Unitaid		
Internal program	ms	Animal Health product (different clinical development process)		



<b>mdc-GRT</b> Tacrolimus Transplantation	<b>mdc-ANG</b> Confidential Antipsychotic						
<b>mdc-STM</b> Ivermectin Malaria	<b>mdc-WWM</b> Progestatif (non-MPA) Contraception	<b>mdc-TJK</b> Confidential Antipsychotic					
mdc-KPT Confidential Pain	<b>mdc-TTG</b> Ivermectine Covid-19	<b>mdc-CWM</b> Celecoxib Pain & inflammation		<b>mdc-IRM</b> Risperidone Schizophrenia			
Preclinical		Phase 1 / 2	Phase 3	NDA <sup>*</sup> / Market			
				*New Drug Application			
In partnership with Teva Pharmaceuticals		Supported by the l	Supported by the Bill & Melinda Gates Foundation				
In partnership with AIC		Supported by Unit	Supported by Unitaid				
Internal programs		Animal Health product (different clinical develop	Animal Health product (different clinical development process)				



Finance results – First semester (April-Sept 2021) Revenue: 4,1 M€ Operating expenses: 15,3 M€ Cash consumption from operations: 11,3 M€

Available Cash as of September 30, 2021

34,4 M€ in cash

3,0 M€ in non risky financial assets

## MedinCell

Thank you

MedinCell 3, rue des frères Lumière 34830 Jacou • France

www.medincell.com